An analysis of the therapeutic benefits of genotyping in pediatric hematopoietic stem cell transplantation

Wright, FA; Bebawy, M; O'Brien, TA

An analysis of the therapeutic benefits of genotyping in pediatric hematopoietic stem cell transplantation

Wright, FA

Bebawy, M

O'Brien, TA

Permalink

Publication Type:: Journal Article
Citation:: Future Oncology, 2015, 11 (5), pp. 833 - 851
Issue Date:: 2015-03-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published VersionAdobe PDF (1.6 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Wright, FA https://orcid.org/0000-0003-2999-0856	en_US
dc.contributor.author	Bebawy, M https://orcid.org/0000-0003-2606-921X	en_US
dc.contributor.author	O'Brien, TA	en_US
dc.date.issued	2015-03-01	en_US
dc.identifier.citation	Future Oncology, 2015, 11 (5), pp. 833 - 851	en_US
dc.identifier.issn	1479-6694	en_US
dc.identifier.uri	http://hdl.handle.net/10453/36406
dc.description.abstract	© 2015 Future Medicine Ltd. Hematopoietic stem cell transplantation is a high-risk procedure that is offered, with curative intent, to patients with malignant and nonmalignant disease. The clinical benefits of personalization of therapy by genotyping have been demonstrated by the reduction in transplant related mortality from donor-recipient HLA matching. However, defining the relationship between genotype and transplant conditioning agents is yet to be translated into clinical practice. A number of the therapeutic agents used in stem cell transplant preparative regimens have pharmacokinetic parameters that predict benefit of incorporating pharmacogenomic data into dosing strategies. Busulfan, cyclophosphamide, thio-TEPA and etoposide have well-described drug metabolism pathways, however candidate gene studies have identified there is a gap in the identification of pharmacogenomic data that can be used to improve transplant outcomes. Incorporating pharmacogenomics into pharmacokinetic modeling may demonstrate the therapeutic benefits of genotyping in transplant preparative regimen agents.	en_US
dc.relation.ispartof	Future Oncology	en_US
dc.relation.isbasedon	10.2217/fon.14.307	en_US
dc.subject.classification	Oncology & Carcinogenesis	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Graft vs Host Disease	en_US
dc.subject.mesh	Isoenzymes	en_US
dc.subject.mesh	Glutathione Transferase	en_US
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols	en_US
dc.subject.mesh	Prognosis	en_US
dc.subject.mesh	Treatment Outcome	en_US
dc.subject.mesh	Lymphocyte Depletion	en_US
dc.subject.mesh	Transplantation Conditioning	en_US
dc.subject.mesh	Life Support Care	en_US
dc.subject.mesh	Hematopoietic Stem Cell Transplantation	en_US
dc.subject.mesh	Transplantation, Homologous	en_US
dc.subject.mesh	Pharmacogenetics	en_US
dc.subject.mesh	Genotype	en_US
dc.subject.mesh	Polymorphism, Genetic	en_US
dc.subject.mesh	Precision Medicine	en_US
dc.title	An analysis of the therapeutic benefits of genotyping in pediatric hematopoietic stem cell transplantation	en_US
dc.type	Journal Article
utslib.citation.volume	5	en_US
utslib.citation.volume	11	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
utslib.for	1112 Oncology and Carcinogenesis	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	open_access
pubs.issue	5	en_US
pubs.publication-status	Published	en_US
pubs.volume	11	en_US

Abstract:

© 2015 Future Medicine Ltd. Hematopoietic stem cell transplantation is a high-risk procedure that is offered, with curative intent, to patients with malignant and nonmalignant disease. The clinical benefits of personalization of therapy by genotyping have been demonstrated by the reduction in transplant related mortality from donor-recipient HLA matching. However, defining the relationship between genotype and transplant conditioning agents is yet to be translated into clinical practice. A number of the therapeutic agents used in stem cell transplant preparative regimens have pharmacokinetic parameters that predict benefit of incorporating pharmacogenomic data into dosing strategies. Busulfan, cyclophosphamide, thio-TEPA and etoposide have well-described drug metabolism pathways, however candidate gene studies have identified there is a gap in the identification of pharmacogenomic data that can be used to improve transplant outcomes. Incorporating pharmacogenomics into pharmacokinetic modeling may demonstrate the therapeutic benefits of genotyping in transplant preparative regimen agents.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/36406